Skin Vaccination against Cervical Cancer Associated Human Papillomavirus with a Novel Micro-Projection Array in a Mouse Model

Cervarix™, the GSK HPV-16/HPV-18 AS04-adjuvanted cervical cancer vaccine, demonstrates stability upon long-term storage and under simulated cold chain break conditions

(2014) David Le Tallec et al.   Human vaccines & immunotherapeutics

Comparison of the immunogenicity and safety ofCervarix™ andGardasil®human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years

(2010) Mark H. Einstein et al.   Human vaccines & immunotherapeutics

Potent Immunity to Low Doses of Influenza Vaccine by Probabilistic Guided Micro-Targeted Skin Delivery in a Mouse Model

(2010) Germain J. P. Fernando et al.   PLoS One

Dry-coated microprojection array patches for targeted delivery of immunotherapeutics to the skin

(2009) Xianfeng Chen et al.   JOURNAL OF CONTROLLED RELEASE

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

(2009) J Paavonen et al.   LANCET

In Vivo Induction of Immune Responses to Pathogens by Conventional Dendritic Cells

(2008) María López-Bravo et al.   IMMUNITY

A Direct Comparison of Human Papillomavirus Type 16 L1 Particles Reveals a Lower Immunogenicity of Capsomeres than Viruslike Particles with Respect to the Induced Antibody Response

(2008) N. Thones et al.   JOURNAL OF VIROLOGY